Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 7/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.43 |
| ▸ | GRM8 | O00222 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8461518 | 0.82 | KCNA5 (0.47) | KCNA5KCNN4GRM8GRM4SMN1; SMN2 | |
| SCHEMBL8460054 | 0.79 | GRM8 (0.48) | KCNA5KCNN4GRM8GRM4SMN1; SMN2 | |
| SCHEMBL8458716 | 0.77 | GRM8 (0.49) | KCNA5KCNN4GRM8GRM4SMN1; SMN2 | |
| SCHEMBL5052872 | 0.76 | GRM8 (0.48) | KCNA5KCNN4GRM8GRM4SMN1; SMN2 | |
| SCHEMBL5051343 | 0.76 | GRM8 (0.43) | KCNA5KCNN4GRM8GRM4SMN1; SMN2 | |
| SCHEMBL5052949 | 0.74 | KCNA5 (0.43) | KCNA5KCNN4GRM8GRM4SMN1; SMN2 | |
| SCHEMBL5053264 | 0.74 | KCNA5 (0.43) | KCNA5KCNN4GRM8GRM4SMN1; SMN2 | |
| SCHEMBL12698775 | 0.74 | SMN1; SMN2 (0.50) | KCNA5SMN1; SMN2CYP2D6CFTRSLC6A2 | |
| SCHEMBL5058022 | 0.73 | ANPEP (0.52) | GRM8GRM4SMN1; SMN2CYP2D6KDM4E | |
| SCHEMBL8461516 | 0.73 | CYP2D6 (0.47) | KCNA5GRM8GRM4SMN1; SMN2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| US-6025345-A | NOVEL PHOSPHONATE DERIVATIVES, HYDROXYPHOSPHINYL DERIVATIVES, AND PHOSPHORAMIDATE DERIVATIVES THAT INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY, | GUILFORD PHARMACEUTICALS INC. (US) | 2000-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | KCNA5 2769/4885KCNN4 4484/4885GRM8 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.